ClinicalTrials.gg
CompletedNCT06721494Updated Nov 10, 2026

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

A Phase 2 interventional study of Methamphetamine and Sterile Saline in Methamphetamine Intoxication, Methamphetamine Disorders and Methamphetamine Abuse, sponsored by Clear Scientific, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Clear Scientific, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

02

Conditions studied

  • Methamphetamine Intoxication
  • Methamphetamine Disorders
  • Methamphetamine Abuse
03

In context

Lead sponsor

Clear Scientific, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Healthy participants aged 18 to 55 years, inclusive;
  2. Meets criteria for methamphetamine use disorder;
  3. Not seeking treatment for methamphetamine use disorder;
  4. Primary route of methamphetamine self-administration must be intravenous or smoking;
  5. Able to abstain from methamphetamine without experiencing severe withdrawal;
  6. A between 18 to 30 kg/m2, inclusive and a minimum body weight of 56 kg;
  7. Females must not be lactating and must have a negative pregnancy test during screening and admission.

Major Exclusion Criteria:

  1. Estimated \<60 mL/min/1.73 m2;
  2. History of cardiovascular disease;
  3. Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;
  4. History of any disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).

    Drug: Methamphetamine · Drug: Sterile Saline

  • Active comparator
    Active

    Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103

    Drug: Methamphetamine · Drug: CS-1103

Interventions

  • Methamphetamine HCl for intravenous administration

  • DrugSterile Saline

    Sterile Saline for intravenous administration

  • CS-1103 for intravenous administration

06

What researchers measure

Primary outcomes

  1. Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinations

    Physical examinations

    Time frame: 3 days plus follow-up on Day 10

  2. Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)

    Digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted.

    Time frame: 3 days plus follow-up on Day 10

  3. Number of participants with CS-1103-related adverse events (AEs) assessed by vital signs

    Blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature

    Time frame: 3 days plus follow-up on Day 10

  4. Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parameters

    Clinical chemistry, hematology, coagulation, and urinalysis

    Time frame: 3 days plus follow-up on Day 10

  5. Time course and magnitude of urine excretion of methamphetamine

    Measurement of concentration of methamphetamine in urine

    Time frame: 48 hours

Secondary outcomes

  1. Time course of CS-1103 blood and urine concentrations

    Measurement of plasma and urine concentrations of CS-1103

    Time frame: 48 hours

07

Study locations

1 site
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Oct 2026, 8 months.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 10, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 6, 2024
StartActual
Feb 5, 2026
Primary completionActual
Oct 24, 2026was Sep 2026
CompletionActual
Oct 29, 2026was Sep 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Sep 4, 2026→Oct 24, 2026 (actual)
moved 2 times, Oct 21, 2026 – Nov 10, 2026
Study completion
Sep 11, 2026→Oct 29, 2026 (actual)
moved 2 times, Oct 21, 2026 – Nov 10, 2026
Enrollment
40 (estimated)→34 (actual)
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Oct 29, 2026→Oct 24, 2026 (now actual)
    Study completion Nov 5, 2026→Oct 29, 2026 (now actual)
    Enrollment 40 (estimated)→34 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details
  2. Oct 21, 2026
    Primary completion Sep 4, 2026→Oct 29, 2026
    Study completion Sep 11, 2026→Nov 5, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06721494
Lead sponsor
Clear Scientific, Inc.
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Feb 5, 2026
Primary completion
Oct 24, 2026
Completion
Oct 29, 2026
Last update
Nov 10, 2026

Study contacts

Xinhua Li, Ph.D.
principal investigator · Clear Scientific, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CS-1103

Start the discussion